This is in agreement with data obtained from HCC patients where Furin overexpression predicts a better postoperative disease-free survival and suggests that Furin inhibition in the liver will not be a good therapeutic strategy for liver cancer [28]. This evidence concerns the gene FURIN and hepatocellular carcinoma.